Rossari Biotech board meeting scheduled for April 27, 2026 to approve audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026.
Board will consider recommending final dividend for financial year 2025-26, subject to approval during the meeting.
Trading window closure for designated persons remains effective from April 1, 2026 until 48 hours after results announcement.
Disclosure made pursuant to SEBI LODR Regulations 29 and 33 regarding board meeting intimation and financial results.